LoveBiome Acquisition Driving Early Momentum
LoveBiome contributed $4.1M of product revenue in Q2 following the October acquisition; successful operational integration, realization of synergies, and multiple product launches (Axila X, Phytopower B) with additional LoveBiome products to launch in coming months. $3.7M cash paid at close plus potential future earn-out.
Product Innovation and Pipeline Strength
Patent-pending P84 positioned as a hero product in gut microbiome market; HealthyEdge stack (Protandim NRS2 + P84) showed supportive third-party cell study results and is resonating as a lead enrollment story.
Technology Modernization via Shopify Partnership
Shopify pilot on track; expected to modernize e-commerce, improve conversion rates and customer experience, and enable enhancements to consultant back-office tools.
Capital Return and Shareholder-Friendly Actions
Board approved new $60M share repurchase authorization and declared a quarterly cash dividend of $0.45 per share; company has returned over $20M to shareholders since fiscal 2024 via dividends and repurchases.
Adjusted Profitability and Sequential Growth
Adjusted EBITDA remained positive at $3.9M (7.9% of revenue) and revenue grew 2.9% sequentially from Q1 to Q2, indicating some stabilization quarter-over-quarter.
Clean Balance Sheet
Ended the quarter with $10.2M cash and no debt, providing financial flexibility despite near-term headwinds.